BCRX
Price
$7.07
Change
-$0.26 (-3.55%)
Updated
Apr 4, 12:02 PM (EDT)
Capitalization
1.53B
27 days until earnings call
DNLI
Price
$12.79
Change
-$0.95 (-6.91%)
Updated
Apr 3 closing price
Capitalization
1.86B
39 days until earnings call
Ad is loading...

BCRX vs DNLI

Header iconBCRX vs DNLI Comparison
Open Charts BCRX vs DNLIBanner chart's image
BioCryst Pharmaceuticals
Price$7.07
Change-$0.26 (-3.55%)
Volume$3.68K
Capitalization1.53B
Denali Therapeutics
Price$12.79
Change-$0.95 (-6.91%)
Volume$1.52M
Capitalization1.86B
BCRX vs DNLI Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. DNLI commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (BCRX: $7.33 vs. DNLI: $12.79)
Brand notoriety: BCRX: Notable vs. DNLI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 90% vs. DNLI: 123%
Market capitalization -- BCRX: $1.53B vs. DNLI: $1.86B
BCRX [@Biotechnology] is valued at $1.53B. DNLI’s [@Biotechnology] market capitalization is $1.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а -6.39% price change this week, while DNLI (@Biotechnology) price change was -9.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.53%. For the same industry, the average monthly price growth was -16.33%, and the average quarterly price growth was -18.08%.

Reported Earning Dates

BCRX is expected to report earnings on May 01, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-10.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.86B) has a higher market cap than BCRX($1.53B). BCRX YTD gains are higher at: -2.527 vs. DNLI (-37.242). BCRX has higher annual earnings (EBITDA): 12.8M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. BCRX (321M). DNLI has less debt than BCRX: DNLI (48.7M) vs BCRX (809M). BCRX has higher revenues than DNLI: BCRX (451M) vs DNLI (0).
BCRXDNLIBCRX / DNLI
Capitalization1.53B1.86B82%
EBITDA12.8M-492.89M-3%
Gain YTD-2.527-37.2427%
P/E RatioN/AN/A-
Revenue451M0-
Total Cash321M832M39%
Total Debt809M48.7M1,661%
FUNDAMENTALS RATINGS
BCRX vs DNLI: Fundamental Ratings
BCRX
DNLI
OUTLOOK RATING
1..100
1469
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
5488
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
4950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (29) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that BCRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

BCRX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as DNLI (100). This means that BCRX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as BCRX (100). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for DNLI (88). This means that BCRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as BCRX (100). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXDNLI
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALPCX10.54N/A
N/A
American Century Focused Lg Cap Val C
GSQRX30.81N/A
N/A
Goldman Sachs Small Cap Value R
MACEX12.86N/A
N/A
Martin Currie Emerging Markets A
TRHZX149.08N/A
N/A
T. Rowe Price Equity Index 500 Z
MIIOX25.32N/A
N/A
Marsico International Opportunities Inst